This medication was approved by the FDA in November 2023 for chronic weight management in adults who are obese or overweight with at least one weight-related condition, such as hypertension, type 2 diabetes, or high cholesterol
Clinical evidence shows improved fasting blood sugar, reduced inflammation markers, better lipid profiles, and lower cardiovascular risk in patients with existing heart disease
Constipation Although less common than diarrhea, some people experience constipation instead
Many of these substances are known triggers of mast cell activation, so reactions to medications can be the medication (the active ingredient) or can be due to an excipient
Unfortunately, the side effects of this medication do include significant diarrhea, which has limited how many people are willing to take this medication